BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 10423033)

  • 1. A novel molecular mechanism modulating osteoclast differentiation and function.
    Yasuda H; Shima N; Nakagawa N; Yamaguchi K; Kinosaki M; Goto M; Mochizuki SI; Tsuda E; Morinaga T; Udagawa N; Takahashi N; Suda T; Higashio K
    Bone; 1999 Jul; 25(1):109-13. PubMed ID: 10423033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.
    Yasuda H; Shima N; Nakagawa N; Yamaguchi K; Kinosaki M; Mochizuki S; Tomoyasu A; Yano K; Goto M; Murakami A; Tsuda E; Morinaga T; Higashio K; Udagawa N; Takahashi N; Suda T
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3597-602. PubMed ID: 9520411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone.
    Tsukii K; Shima N; Mochizuki S; Yamaguchi K; Kinosaki M; Yano K; Shibata O; Udagawa N; Yasuda H; Suda T; Higashio K
    Biochem Biophys Res Commun; 1998 May; 246(2):337-41. PubMed ID: 9610359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
    Takahashi N; Udagawa N; Suda T
    Biochem Biophys Res Commun; 1999 Mar; 256(3):449-55. PubMed ID: 10080918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular basis of osteoclast differentiation and activation.
    Suda T; Kobayashi K; Jimi E; Udagawa N; Takahashi N
    Novartis Found Symp; 2001; 232():235-47; discussion 247-50. PubMed ID: 11277084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.
    Suda T; Takahashi N; Udagawa N; Jimi E; Gillespie MT; Martin TJ
    Endocr Rev; 1999 Jun; 20(3):345-57. PubMed ID: 10368775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation.
    Nagai M; Sato N
    Biochem Biophys Res Commun; 1999 Apr; 257(3):719-23. PubMed ID: 10208850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
    Takayanagi H; Iizuka H; Juji T; Nakagawa T; Yamamoto A; Miyazaki T; Koshihara Y; Oda H; Nakamura K; Tanaka S
    Arthritis Rheum; 2000 Feb; 43(2):259-69. PubMed ID: 10693864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.
    Hofbauer LC; Khosla S; Dunstan CR; Lacey DL; Boyle WJ; Riggs BL
    J Bone Miner Res; 2000 Jan; 15(1):2-12. PubMed ID: 10646108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.
    Yasuda H; Shima N; Nakagawa N; Mochizuki SI; Yano K; Fujise N; Sato Y; Goto M; Yamaguchi K; Kuriyama M; Kanno T; Murakami A; Tsuda E; Morinaga T; Higashio K
    Endocrinology; 1998 Mar; 139(3):1329-37. PubMed ID: 9492069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas.
    Kumamoto H; Ooya K
    J Oral Pathol Med; 2004 Jan; 33(1):46-52. PubMed ID: 14675140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
    Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
    Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.
    Matsuzaki K; Udagawa N; Takahashi N; Yamaguchi K; Yasuda H; Shima N; Morinaga T; Toyama Y; Yabe Y; Higashio K; Suda T
    Biochem Biophys Res Commun; 1998 May; 246(1):199-204. PubMed ID: 9600092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
    Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
    J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.
    Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Yano K; Morinaga T; Higashio K
    Biochem Biophys Res Commun; 1998 Dec; 253(2):395-400. PubMed ID: 9878548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basic fibroblast growth factor inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D(3) through suppressing the production of osteoclast differentiation factor.
    Nakagawa N; Yasuda H; Yano K; Mochizuki Si; Kobayashi N; Fujimoto H; Yamaguchi K; Shima N; Morinaga T; Higashio K
    Biochem Biophys Res Commun; 1999 Nov; 265(1):45-50. PubMed ID: 10548488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF).
    Gao YH; Shinki T; Yuasa T; Kataoka-Enomoto H; Komori T; Suda T; Yamaguchi A
    Biochem Biophys Res Commun; 1998 Nov; 252(3):697-702. PubMed ID: 9837769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.